Caraco Pharmaceutical Laboratories has announced that it will slash around half of its work force to realign expenses after the US Food and Drug Administration (FDA) seized up to 33 of the company’s generic drugs due to manufacturing violations.

In June 2009 the FDA seized drugs made at the company’s Michigan facilities in Detroit, Farmington Hills and Wixom.

Among the drugs were generic versions of heart, pain and psychiatric drugs as well as the epilepsy treatment Tegretol and a generic copy of the diabetes drug Glucophage.

The company will now eliminate around 350 positions, around half of its workforce, after suspending all manufacturing until talks are concluded with the FDA.

According to the Wall Street Journal shares in Caraco have fallen 3.2% to $3.05.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData